CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 255 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06499571
NCT06499571N/ACompleted

G.A.L.T.O.S. Geographic Atrophy Long-Terms Outcomes Study: An Ambispective Noninterventional Study to Describe the Patient Demographics and Outcomes of Patients With Geographic Atrophy (GA) Secondary to AMD in Clinical Practice

Apellis Pharmaceuticals, Inc.·observational·Posted Jul 12, 2024·Updated Jul 12, 2024

In Brief

An observational study for Geographic Atrophy. Completed, enrolled 255 participants across 5 sites in 5 countries.

Detailed Summary

The purpose of this study is to describe functional and long-term clinical outcomes of patients with a diagnosis of Geographic Athrophy secondary to Age related Macular Degenaration in Clinical Practice

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, France, Germany, Italy, United Kingdom
CollaboratorsIQVIA Pty Ltd

Timeline

N/ACompletedFinished
2023202420252026
First PostedJul 12, 2024
Enrollment StartSep 1, 2022
Primary CompletionJul 31, 2023
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 2.0 years ago